Pelgraz

Cancer

Accord’s biosimilar Pelgraz poised for approval

Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks